INmune Bio Inc (INMB) concluded trading on Thursday at a closing price of $6.28, with 3.19 million shares of worth about $20.06 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 42.73% during that period and on June 26, 2025 the price saw a loss of about -14.79%. Currently the company’s common shares owned by public are about 22.93M shares, out of which, 16.50M shares are available for trading.
Stock saw a price change of -13.26% in past 5 days and over the past one month there was a price change of -17.91%. Year-to-date (YTD), INMB shares are showing a performance of -16.60% which increased to 34.48% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.32 but also hit the highest price of $10.50 during that period. The average intraday trading volume for INmune Bio Inc shares is 439.39K. The stock is currently trading -13.99% below its 20-day simple moving average (SMA20), while that difference is down -15.86% for SMA50 and it goes to -6.63% lower than SMA200.
INmune Bio Inc (NASDAQ: INMB) currently have 22.93M outstanding shares and institutions hold larger chunk of about 25.53% of that.
The stock has a current market capitalization of $145.76M and its 3Y-monthly beta is at 1.56. It has posted earnings per share of -$1.95 in the same period. It has Quick Ratio of 2.64 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INMB, volatility over the week remained 17.13% while standing at 9.78% over the month.
Analysts are in expectations that INmune Bio Inc (INMB) stock would likely to be making an EPS of -0.43 in the current quarter, while forecast for next quarter EPS is -0.41 and it is -1.6 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.48 which is -0.37 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 20.36% while it is estimated to decrease by -0.58% in next year. EPS is likely to grow at an annualized rate of 14.10% for next 5-years, compared to annual growth of -23.07% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on January 28, 2025 offering a Buy rating for the stock and assigned a target price of $23 to it. Coverage by Alliance Global Partners stated INmune Bio Inc (INMB) stock as a Buy in their note to investors on October 21, 2024, suggesting a price target of $20 for the stock. On September 27, 2024, Raymond James Initiated their recommendations, while on August 22, 2024, Scotiabank Initiated their ratings for the stock with a price target of $22. Stock get an Outperform rating from Robert W. Baird on June 01, 2023.
